EQS Group-Media / 2019-11-04 / 19:00
*Media Release*
*Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA
Clearance*
_CASTEL SAN PIETRO_, _4 November 2019_ - Medacta is proud to announce the
successful completion of the first U.S. surgery utilizing its MectaScrew
PEEK Interference Screw for ligament refixation.
The MectaScrew PEEK, which received clearance from the U.S. Food and Drug
Administration (FDA) in June, is one of Medacta's most recent sports
medicine offerings. As part of the Medacta Single Bundle ACL set, it is
intended for knee arthroscopy and indicated for reconstructive treatment of
ruptured anterior and posterior cruciate ligaments for hamstring and
bone-tendon-bone repairs.
The MectaScrew PEEK features several noteworthy design features, including a
blunt thread, which protects the graft from laceration, while ensuring
fixation strength, as well as sharp threads at the driver tip that gradually
increase in width as the screw goes from distal to proximal to facilitate
screw insertion. The associated driver also features a tip design that
enables strong retention of the screw once positioned on the tip of the
instrument.
The first single bundle ACL surgery in the United States was completed by
Akbar Nawab, M.D., at Ellis and Badenhausen Orthopaedics (Louisville,
Kentucky) on September 24. "The implant and associated instrumentation
performed very well," said Dr. Nawab. "The screw started nicely and provided
secure fixation without any damage to the graft, while the instrumentation's
ergonomic design made each instrument easy and natural to use. I feel very
confident starting my patient in an accelerated rehabilitation program."
This surgery follows the first single bundle ACL performed in Australia in
August 2019 and is the start of Medacta's sports medicine presence in the
United States.
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specializing in the design and
production of innovative orthopaedic products and the development of
accompanying surgical techniques for joint replacement, spine surgery, and
sports medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "MySolutions" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Advertisement/Communication
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 903815
End of News EQS Group Media
903815 2019-11-04
(END) Dow Jones Newswires
November 04, 2019 13:00 ET (18:00 GMT)
